Radiopharm Theranostics Limited Sponsored ADR (RADX)
NASDAQ:RADX
Want to see RADX full AI Analyst Report?
Top Page
Radiopharm Theranostics Limited Sponsored ADR
(NASDAQ:RADX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$4.00
▼(-12.66% Downside)
Action:ReiteratedDate:03/25/26
The score is held down primarily by persistent losses and ongoing cash burn, despite a debt-free balance sheet. Technical indicators also remain bearish with the stock trading below key moving averages and a negative MACD. Valuation support is limited because the company is unprofitable (negative P/E) and offers no dividend yield.
Positive Factors
Debt-free balance sheet
Zero reported debt materially lowers refinancing risk and gives Radiopharm flexibility to fund R&D and JV commitments without immediate interest burdens. Over a multi‑month horizon this conservative leverage profile preserves strategic optionality while the company advances clinical programs.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow indicates ongoing burn to support development activities. Over the medium term this constrains the company’s ability to self‑fund parallel programs, forcing reliance on financings or partnerships that can dilute shareholders or delay investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt materially lowers refinancing risk and gives Radiopharm flexibility to fund R&D and JV commitments without immediate interest burdens. Over a multi‑month horizon this conservative leverage profile preserves strategic optionality while the company advances clinical programs.
Read all positive factors
Radiopharm Theranostics Limited Sponsored ADR (RADX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$51.36M
Dividend YieldN/A
Average Volume (3M)287.79K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue Growth110.08%
EPS Growth76.04%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.11
Shares Outstanding11,814,054
10 Day Avg. Volume45,935
30 Day Avg. Volume287,787
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.09
Price to Sales (P/S)13.46
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$22.50Price Target Upside391.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.09
Revenue Forecast (FY)$788.12K
Radiopharm Theranostics Limited Sponsored ADR Business Overview & Revenue Model
Company Description
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the trea...
How the Company Makes Money
null...
Radiopharm Theranostics Limited Sponsored ADR Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 3.63M | 299.23K | 292.36K | 8.83K |
| Gross Profit | 39.28K | 299.23K | 292.36K | 8.83K |
| EBITDA | -38.17M | -44.08M | -31.19M | -17.96M |
| Net Income | -38.34M | -47.95M | -34.61M | -30.34M |
Balance Sheet | ||||
| Total Assets | 86.48M | 72.04M | 74.95M | 83.38M |
| Cash, Cash Equivalents and Short-Term Investments | 29.12M | 18.58M | 11.70M | 26.98M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 43.61M | 44.68M | 29.37M | 20.42M |
| Stockholders Equity | 44.79M | 28.12M | 44.38M | 62.96M |
Cash Flow | ||||
| Free Cash Flow | -36.65M | -22.98M | -24.73M | -38.25M |
| Operating Cash Flow | -36.65M | -22.98M | -23.20M | -9.92M |
| Investing Cash Flow | 1.77M | -320.00K | -1.53M | -28.37M |
| Financing Cash Flow | 45.43M | 30.20M | 9.22M | 65.11M |
Radiopharm Theranostics Limited Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $80.98M | -1.22 | -57.23% | ― | ― | 16.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $26.86M | -1.05 | -70.57% | ― | -100.00% | 21.30% | |
46 Neutral | $51.36M | -1.28 | -105.17% | ― | 110.08% | 76.04% | |
46 Neutral | $27.26M | -1.46 | -1259.21% | ― | ― | ― | |
42 Neutral | $26.92M | -0.31 | 763.31% | ― | -51.03% | -35.20% |
* Healthcare Sector Average
RADX
Radiopharm Theranostics Limited Sponsored ADR
4.25
-0.09
-2.07%
SER
Serina Therapeutics
1.83
-3.92
-68.17%
CELU
Celularity
0.93
-0.74
-44.31%
BRNS
Barinthus Biotherapeutics
0.66
-0.33
-33.57%
ACRV
Acrivon Therapeutics, Inc.
2.09
0.86
69.92%
TELO
Telomir Pharmaceuticals, Inc.
1.34
-1.15
-46.18%
Radiopharm Theranostics Limited Sponsored ADR Corporate Events
Radiopharm Theranostics Doses First Patient in Phase 1/2a Trial of 177Lu-BetaBart
Feb 24, 2026
On 24 February 2026 Radiopharm Theranostics announced it had dosed the first patient in a First-In-Human Phase 1/2a clinical trial of 177Lu-BetaBart (RV-01), a radiotherapeutic developed through Radiopharm Ventures, its joint venture with The Univ...
Radiopharm Theranostics Lifts Stake in MD Anderson Joint Venture to 87.5% as Lead B7H3 Drug Enters Clinic
Jan 12, 2026
On 12 January 2026, Radiopharm Theranostics announced it had increased its ownership stake in Radiopharm Ventures, LLC, its radiopharmaceutical joint venture with The University of Texas MD Anderson Cancer Center, from 75% to 87.5%, signalling hei...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.